| pubmed-article:1919536 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1919536 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:1919536 | lifeskim:mentions | umls-concept:C0009462 | lld:lifeskim |
| pubmed-article:1919536 | lifeskim:mentions | umls-concept:C0750484 | lld:lifeskim |
| pubmed-article:1919536 | lifeskim:mentions | umls-concept:C0033105 | lld:lifeskim |
| pubmed-article:1919536 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
| pubmed-article:1919536 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1919536 | pubmed:dateCreated | 1991-11-18 | lld:pubmed |
| pubmed-article:1919536 | pubmed:abstractText | The prevalence of antibody to hepatitis C virus (HCV) was estimated in 3 tropical populations using 2 screening ELISAs to detect antibody to the c100-3 antigen and 2 supplementary assays designed to test the specificity of these tests. Two hundred and eighty-six of 385 (74.2%) sera from Kiribati, 17 of 138 (12.3%) sera from Vanuatu, and 39 of 173 (22.5%) sera from Zaire were reactive in the initial screening assay. The proportion of reactive sera which were also reactive in the second screening ELISA varied between populations (55.1% in Kiribati, 85.1% in Vanuatu, and 39.2% from Zaire). Reactive sera were selected at random for confirmatory testing. Only 3 of 49 (6.12%) of sera from Kiribati and 1 of 14 (4.76%) of sera from Vanuatu positive in the initial ELISA were reactive in the confirmatory assays. The proportion of confirmed positive sera from Zaire was higher 8 of 28 (28.5%). Based on the results of these supplementary assays the estimated prevalence of anti-HCV in these populations is 4.8% in Kiribati, less than 1% in Vanuatu, and 6.4% in Zaire. Reliance on a single screening ELISA to estimate the prevalence of anti-HCV in stored sera from tropical communities may lead to a gross over-estimate of the true prevalence in these populations. | lld:pubmed |
| pubmed-article:1919536 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1919536 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1919536 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1919536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1919536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1919536 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1919536 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1919536 | pubmed:issn | 0146-6615 | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:PalmerS JSJ | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:BanatvalaJ... | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:HojvatSS | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:PetersonDD | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:ClarkS KSK | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:CokerRR | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:TibbsC JCJ | lld:pubmed |
| pubmed-article:1919536 | pubmed:author | pubmed-author:ParsonsG MGM | lld:pubmed |
| pubmed-article:1919536 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1919536 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:1919536 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1919536 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1919536 | pubmed:pagination | 143-7 | lld:pubmed |
| pubmed-article:1919536 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:meshHeading | pubmed-meshheading:1919536-... | lld:pubmed |
| pubmed-article:1919536 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1919536 | pubmed:articleTitle | Prevalence of hepatitis C in tropical communities: the importance of confirmatory assays. | lld:pubmed |
| pubmed-article:1919536 | pubmed:affiliation | Department of Virology, United Medical School, Guy's Hospital, London, England. | lld:pubmed |
| pubmed-article:1919536 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1919536 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1919536 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1919536 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1919536 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1919536 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1919536 | lld:pubmed |
